Patient Peter Almond told of his disappointment that donanemab will only be available to those who can pay for a private ...

Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U.S. marketing approval. What ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...

Adding 75mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million. HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to ...

This is the second time a new Alzheimer's treatment has been rejected by the health spending watchdog in a matter of months.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as momentous. Finally, for the first time, a drug had slowed the ...

Lecanemab's weight-based dosing and single-use vials result in significant drug wastage, impacting Medicare spending. An analysis estimated $133 million to $336 million in wasted spending due to ...

Making a 75-milligram vial available alongside the two current options of 200 milligrams and 500 milligrams could save ...

Pet insurance can absorb some of the financial impact: Accident-only insurance covers emergencies like broken bones or swallowed objects, while accident and illness policies can also include ...

STOCKHOLM, Oct. 16, 2024 /PRNewswire/ --BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public ...